Published in World J Biol Psychiatry on March 01, 2010
Recent advances in quantitative neuroproteomics. Methods (2013) 1.23
The role of proteomics in depression research. Eur Arch Psychiatry Clin Neurosci (2009) 1.03
Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry (2012) 1.02
Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. Eur Arch Psychiatry Clin Neurosci (2012) 0.92
The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia. BMC Res Notes (2012) 0.89
Proteomics tackling schizophrenia as a pathway disorder. Schizophr Bull (2012) 0.87
Psychoactive pharmaceuticals induce fish gene expression profiles associated with human idiopathic autism. PLoS One (2012) 0.84
CRMPs: critical molecules for neurite morphogenesis and neuropsychiatric diseases. Mol Psychiatry (2015) 0.83
Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia. Eur Arch Psychiatry Clin Neurosci (2010) 0.81
Reduced expression of STOP/MAP6 in mice leads to cognitive deficits. Schizophr Bull (2012) 0.80
Structural basis for the association of MAP6 protein with microtubules and its regulation by calmodulin. J Biol Chem (2013) 0.79
Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders. Int J Neuropsychopharmacol (2015) 0.79
The proteome of schizophrenia. NPJ Schizophr (2015) 0.79
Mitochondrial dysfunction in schizophrenia: an evolutionary perspective. Hum Genet (2014) 0.78
Proteomics as a tool for understanding schizophrenia. Clin Psychopharmacol Neurosci (2011) 0.77
Effect of MK-801 and Clozapine on the Proteome of Cultured Human Oligodendrocytes. Front Cell Neurosci (2016) 0.76
Schizophrenic: forever young? Genome Med (2010) 0.76
Proteomic and Microscopic Strategies towards the Analysis of the Cytoskeletal Networks in Major Neuropsychiatric Disorders. Int J Mol Sci (2016) 0.75
The potential of biomarkers in psychiatry: focus on proteomics. J Neural Transm (Vienna) (2013) 0.75
Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med (2006) 4.16
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 3.86
Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry (2010) 3.42
Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. Br J Psychiatry (2005) 2.84
Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nat Genet (2003) 2.66
microRNA-34c is a novel target to treat dementias. EMBO J (2011) 2.44
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry (2011) 2.20
Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J Clin Psychiatry (2014) 2.13
Fear is only as deep as the mind allows: a coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect. Neuroimage (2011) 2.02
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry (2007) 1.95
Detection by polymerase chain reaction of Schistosoma mansoni DNA in human serum and feces. Am J Trop Med Hyg (2002) 1.92
World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res (2008) 1.84
ABRF-PRG03: phosphorylation site determination. J Biomol Tech (2003) 1.83
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One (2010) 1.62
Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. Eur Arch Psychiatry Clin Neurosci (2008) 1.55
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Increased stress reactivity is associated with reduced hippocampal activity and neuronal integrity along with changes in energy metabolism. Eur J Neurosci (2012) 1.54
Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry (2012) 1.53
Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathol (2008) 1.51
Comparison of a polymerase chain reaction and the Kato-Katz technique for diagnosing infection with Schistosoma mansoni. Am J Trop Med Hyg (2003) 1.49
Large-scale transcriptome analyses reveal new genetic marker candidates of head, neck, and thyroid cancer. Cancer Res (2005) 1.47
Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry (2010) 1.45
Protective drugs in acute large-dose exposure to organophosphates: a comparison of metoclopramide and tiapride with pralidoxime in rats. Anesth Analg (2005) 1.45
The role of the human ventral striatum and the medial orbitofrontal cortex in the representation of reward magnitude - an activation likelihood estimation meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing. Neuropsychologia (2012) 1.44
Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. J Biol Chem (2003) 1.40
Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci (2005) 1.40
Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. Exp Gerontol (2005) 1.39
Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol (2002) 1.39
[The confused patient]. MMW Fortschr Med (2014) 1.38
Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: a BrainNet Europe study. Brain Pathol (2007) 1.36
A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull (2003) 1.34
Effects of antipsychotics on brain structure. Curr Opin Psychiatry (2006) 1.33
Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci Biobehav Rev (2006) 1.30
The Drosophila myosin VI Jaguar is required for basal protein targeting and correct spindle orientation in mitotic neuroblasts. Dev Cell (2003) 1.26
Functional neuroimaging of reward processing and decision-making: a review of aberrant motivational and affective processing in addiction and mood disorders. Brain Res Rev (2008) 1.25
Genetic load on amygdala hypofunction during sadness in nonaffected brothers of schizophrenia patients. Am J Psychiatry (2004) 1.24
Discovery of a functional protein complex of netrin-4, laminin gamma1 chain, and integrin alpha6beta1 in mouse neural stem cells. Proc Natl Acad Sci U S A (2009) 1.24
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.24
Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2009) 1.23
ABRF-PRG04: differentiation of protein isoforms. J Biomol Tech (2007) 1.22
Cognitive effects of high-frequency repetitive transcranial magnetic stimulation: a systematic review. J Neural Transm (Vienna) (2009) 1.22
Common and distinct neural correlates of emotional processing in Bipolar Disorder and Major Depressive Disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies. Eur Neuropsychopharmacol (2011) 1.21
Neural correlates of working memory dysfunction in first-episode schizophrenia patients: an fMRI multi-center study. Schizophr Res (2006) 1.21
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry (2007) 1.19
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol (2009) 1.19
Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex (2002) 1.18
Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci (2011) 1.18
Multifocal slow potential generation revealed by high-resolution EEG and current density reconstruction. Int J Psychophysiol (2002) 1.17
Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry (2005) 1.17
Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch Gen Psychiatry (2010) 1.17
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry (2005) 1.16
Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: relation to performance and clinical symptoms. J Psychiatr Res (2009) 1.16
The generators of slow potentials obtained during verbal, pictorial and spatial tasks. Int J Psychophysiol (2003) 1.16
Proteomics and metabolomics analysis of a trait anxiety mouse model reveals divergent mitochondrial pathways. Biol Psychiatry (2011) 1.14
Mining the human cerebrospinal fluid proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis (2004) 1.13
Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord (2005) 1.12
Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch Gen Psychiatry (2005) 1.11
The effects of physical exercise in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.11
Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis. Eur Arch Psychiatry Clin Neurosci (2006) 1.11
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm (Vienna) (2008) 1.10
Does lithium prevent Alzheimer's disease? Drugs Aging (2012) 1.10
The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry (2010) 1.10
Effects of aerobic exercise on cognitive performance and individual psychopathology in depressive and schizophrenia patients. Eur Arch Psychiatry Clin Neurosci (2014) 1.10
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry (2006) 1.10
Saci-1, -2, and -3 and Perere, four novel retrotransposons with high transcriptional activities from the human parasite Schistosoma mansoni. J Virol (2004) 1.09
Neural substrates of olfactory processing in schizophrenia patients and their healthy relatives. Psychiatry Res (2007) 1.09
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A (2011) 1.09
Reduced cortical folding in schizophrenia: an MRI morphometric study. Am J Psychiatry (2003) 1.08
Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res (2008) 1.08
MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol (2011) 1.08
Biomphalaria glabrata transcriptome: identification of cell-signalling, transcriptional control and immune-related genes from open reading frame expressed sequence tags (ORESTES). Dev Comp Immunol (2006) 1.08